Description

In this episode, we focus on the history of researchers discovering the clinical applicability of the IL 23/17 axis, with a particular emphasis on psoriasis, psoriatic arthritis and axial SpA

• Intro 0:15
• In this episode 0:27
• Leonard Calabrese, DO, is listening! 1:07
• Recap of last episode 3:23
• Putting the pieces together 5:32
• Quick overview of this science heavy episode 6:27
• What is psoriasis? 7:42
• Immunosuppressants for psoriasis/ Throwing meds at people and seeing what happens 10:20
• In the modern world of 1986 – olive oil placebo trial 11:45
• A quick aside into fungi 12:44
• What kind of T-cells are involved here? 16:50
• The TH-1 hypothesis 18:31
• IL-23 and IL-17 are doing something 19:38
• Going back to the drawing board in 2004 20:12
• p40 + p19 = IL-23 21:08
• IL-23 via minicircle DNA in mice 23:09
• Brand new and shiny TH-17 25:30
• The family of IL-17 26:40
• What do we know about IL-17 and psoriasis? 27:17
• IL-17A vs IL-17F in mouse studies 27:42
• Finding the difference between IL-17A and IL-17F in humans 28:30
• What exactly is IL-17 doing? 29:51
• The articular manifestations of psoriatic arthritis 31:13
• Spondylarthritis and the IL 23/17 axis 34:10
• T-cells we haven't talked about 35:49
• Summary of this episode 39:17
• Thanks for listening 41:38

We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

References:

Bashyam H. J Exp Med. 2007;doi:10.1084/jem.2042fta

Bjerke R J. Acta Derm Venereol. 1982;PMID:6179355

Cargill M, et al. Am J Hum Genet. 2007;doi:10.1086/511051

Chan J R, et al. J Exp Med. 2006;doi:10.1084/jem.20060244

Cuthbert R J, et al. Ann Rheum Dis. 2019;doi:10.1136/annrheumdis-2019-215210

Ellis C N, et al. JAMA. 1986;doi:10.1001/jama.1986​

Ettehadi P, et al. Clin Exp Immunol. 1994;doi:10.1111/j.1365-2249.1994.tb06244.x

Furue M, et al. Int J Mol Sci. 2020;doi:10.3390/ijms21041275

Gooderham M J, et al. J Eur Acad Dermatol Venereol. 2018;doi:10.1111/jdv.14868

Lee E, et al. J Exp Med. 2004;doi:10.1084/jem.20030451

Leonardi C L, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60725-4

Mease P J, et al. Lancet. 2000;doi:10.1016/S0140-6736(00)02530-7

Menon B, et al. Arthritis Rheumatol. 2014;doi:10.1002/art.38376

Moos S, et al. J Invest Dermatol. 2019;doi:10.1016/j.jid.2019.01.006

Muelle W, et al. N Engl J Med. 1979;doi:10.1056/NEJM197909063011016

Papp K A, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60726-6

Reinhardt A, et al. Arthritis Rheumatol. 2016;doi:10.1002/art.39732

Sherlock J P, et al. Nat Med. 2012;doi:10.1038/nm.2817

Tribe H T. Mycologist. 1998;doi:10.1016/S0269-915X(98)80100-6

Yawalkar N, et al. J Invest Dermatol. 1998;doi:10.1046/j.1523-1747.1998.00446.x

Zaba L C, et al. J Allergy Clin Immunol. 2009;doi:10.1016/j.jaci.2009.08.046

Disclosures: Brown reports no relevant financial disclosures.